| dc.relation | International Agency for Research on Cancer. Global Cancer Observatory [Internet]. World Health Organization; 2021 [Consultado 2021]. Available from: https://gco.iarc.fr/ 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254 3. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomark Cancer. 2019;11:1179299X1986081. doi: 10.1177/1179299X19860815 4. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. http://dx.doi.org/10.1016/j.bpobgyn.2016.08.006} 5. Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, et al. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. JAMA Netw open. 2020;3(8):e2013940. doi: 10.1001/jamanetworkopen.2020.13940 6. Monk BJ, Randall LM, Grisham RN. The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ B. 2019;39:e141–51. doi: 10.1200/EDBK_239007 7. Trimbos JB. Surgical treatment of early-stage ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41(2017):60–70. http://dx.doi.org/10.1016/j.bpobgyn.2016.10.001 8. Bois A Du, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. doi: 10.1002/cncr.24149 9. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010 10. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020;11: 577869. doi: 10.3389/fimmu.2020.577869 11. Broekman KE, van Kruchten M, van Tinteren H, Sessa C, Jalving M, Reyners AKL. Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores. ESMO Open. 2021;6(4):100229. https://doi.org/10.1016/j.esmoop.2021.100229 12. Isabelle RC, Isabelle TF, Eric PL, Liu JF, Selle F, Poveda AM, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 2016;34(36):4345–53. doi: 10.1200/JCO.2016.67.1891 13. Murphy M, Martin G, Mahmoudjafari Z, Bivona C, Grauer D, Henry D. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. J Oncol Pharm Pract. 2020;26(7):1566–74. doi: 10.1177/1078155219899460 14. Du Bois A, Lück HJ, Meier W et al. No TitCarboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.le. Semin Onco. 1997;24(5):s15–52. 15. Coleman RL, Hennessy BT, Coleman RL, Markman M. Fallopian, Including Cancer, Tube Cancer, Primary Peritoneal. NCCN. 2021;1. 16. Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014 17. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505. doi: 10.1056/NEJMoa1810858 18. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. doi: 10.1200/JCO.2003.02.153 19. Huang CY, Cheng M, Lee NR, Huang HY, Lee WL, Chang WH, et al. Comparing paclitaxel-"carboplatin with paclitaxel-"cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer. Int J Environ Res Public Health. 2020;17(7):2213. doi: 10.3390/ijerph17072213 | |
